SPOTLIGHT: Glaxo wraps up Reliant buy

GlaxoSmithKline says it's completed its $1.65 billion buyout of U.S.-based heart drug specialist Reliant Pharmaceuticals; the Federal Trade Commission ended the mandatory antitrust waiting period early. Release

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.